KRSNAA

Krsnaa Diagnostics Share Price

₹727.80 -16.75 (-2.25%)

22 Feb, 2025 21:47

SIP TrendupStart SIP in KRSNAA

Start SIP

Performance

  • Low
  • ₹720
  • High
  • ₹761
  • 52 Week Low
  • ₹528
  • 52 Week High
  • ₹1,044
  • Open Price₹746
  • Previous Close₹745
  • Volume42,255

Investment Returns

  • Over 1 Month -13.01%
  • Over 3 Month -22.14%
  • Over 6 Month + 0.85%
  • Over 1 Year + 6.9%
SIP Lightning

Smart Investing Starts Here Start SIP with Krsnaa Diagnostics for Steady Growth!

Invest Now

Krsnaa Diagnostics Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 31.1
  • PEG Ratio
  • 1
  • Market Cap Cr
  • 2,350
  • P/B Ratio
  • 2.8
  • Average True Range
  • 39.8
  • EPS
  • 23.43
  • Dividend Yield
  • 0.3
  • MACD Signal
  • -27.03
  • RSI
  • 33.04
  • MFI
  • 19.79

Krsnaa Diagnostics Financials

Krsnaa Diagnostics Technicals

EMA & SMA

Current Price
₹727.80
-16.75 (-2.25%)
pointer
  • stock-down_img
  • Bullish Moving Average 1
  • stock-up_img
  • Bearish Moving Average 15
  • 20 Day
  • ₹794.06
  • 50 Day
  • ₹837.12
  • 100 Day
  • ₹840.88
  • 200 Day
  • ₹798.64

Resistance and Support

736.27 Pivot Speed
  • R3 793.53
  • R2 777.27
  • R1 752.53
  • S1 711.53
  • S2 695.27
  • S3 670.53

What's your outlook on Krsnaa Diagnostics?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Krsnaa Diagnostics Ltd. is a leading provider of diagnostic and imaging services in India, specializing in radiology, pathology, and health check-ups. The company focuses on delivering high-quality, affordable healthcare solutions, enhancing patient access to diagnostic services across various regions.

Krsnaa Diagnostics has an operating revenue of Rs. 697.37 Cr. on a trailing 12-month basis. An annual revenue growth of 26% is outstanding, Pre-tax margin of 11% is healthy, ROE of 7% is fair but needs improvement. The company has a reasonable debt to equity of 1%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 54 which is a POOR score indicating inconsistency in earnings, a RS Rating of 63 which is FAIR indicating the recent price performance, Buyer Demand at D+ which indicates heavy supply, Group Rank of 79 indicates it belongs to a poor industry group of Medical-Services and a Master Score of B is close to being the best. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Krsnaa Diagnostics Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-02-12 Quarterly Results
2024-10-25 Quarterly Results
2024-08-06 Quarterly Results
2024-05-18 Audited Results & Final Dividend
2024-02-12 Quarterly Results
Date Purpose Remarks
2024-09-13 FINAL Rs.2.50 per share(50%)Final Dividend
2022-09-16 FINAL Rs.2.50 per share(50%)Final Dividend

Krsnaa Diagnostics F&O

Krsnaa Diagnostics Shareholding Pattern

27.24%
9.82%
2.95%
4.04%
29.1%
26.85%

About Krsnaa Diagnostics

  • NSE Symbol
  • KRSNAA
  • BSE Symbol
  • 543328
  • ISIN
  • INE08LI01020

Similar Stocks to Krsnaa Diagnostics

Krsnaa Diagnostics FAQs

Krsnaa Diagnostics share price is ₹727 As on 22 February, 2025 | 21:33

The Market Cap of Krsnaa Diagnostics is ₹2350.1 Cr As on 22 February, 2025 | 21:33

The P/E ratio of Krsnaa Diagnostics is 31.1 As on 22 February, 2025 | 21:33

The PB ratio of Krsnaa Diagnostics is 2.8 As on 22 February, 2025 | 21:33

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23